Crossmark Global Holdings, Inc. Amgen Inc Transaction History

Crossmark Global Holdings, Inc.

$5.23 Billion
Q2 2024

A detailed history of Crossmark Global Holdings, Inc. transactions in Amgen Inc stock. As of the latest transaction made, Crossmark Global Holdings, Inc. holds 75,158 shares of AMGN stock, worth $24.3 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares

75,158

Previous 93,535 19.65%

Holding current value

$24.3 Million

Previous $26.6 Million 11.69%

% of portfolio

0.45%

Previous 0.51%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 29, 2024	SELL	$262.75 - $319.31 $4.83 Million - $5.87 Million	-18,377 Reduced 19.65%	75,158 $23.5 Million
Q1 2024 May 13, 2024	SELL	$268.87 - $324.56 $5.35 Million - $6.45 Million	-19,880 Reduced 17.53%	93,535 $26.6 Million
Q4 2023 Feb 13, 2024	BUY	$255.7 - $288.46 $124,525 - $140,480	487 Added 0.43%	113,415 $32.7 Million
Q3 2023 Nov 08, 2023	BUY	$218.65 - $271.46 $10.2 Million - $12.6 Million	46,426 Added 69.81%	112,928 $30.6 Million
Q2 2023 Jul 31, 2023	SELL	$214.27 - $253.37 $601,455 - $711,209	-2,807 Reduced 4.05%	66,502 $15.7 Million
Q1 2023 May 12, 2023	BUY	$225.79 - $275.2 $366,005 - $446,099	1,621 Added 2.39%	69,309 $16.8 Million
Q4 2022 Jan 19, 2023	BUY	$229.03 - $291.01 $759,921 - $965,571	3,318 Added 5.15%	67,688 $17.8 Million
Q3 2022 Nov 01, 2022	BUY	$224.46 - $253.15 $1.94 Million - $2.18 Million	8,621 Added 15.46%	64,370 $14.5 Million
Q2 2022 Jul 29, 2022	SELL	$230.71 - $256.74 $9.98 Million - $11.1 Million	-43,279 Reduced 43.7%	55,749 $13.6 Million
Q1 2022 May 11, 2022	SELL	$219.27 - $242.57 $142,306 - $157,427	-649 Reduced 0.65%	99,028 $23.9 Million
Q4 2021 Jan 10, 2022	SELL	$198.88 - $227.6 $599,225 - $685,758	-3,013 Reduced 2.93%	99,677 $22.4 Million
Q3 2021 Oct 21, 2021	BUY	$212.27 - $248.7 $15.2 Million - $17.8 Million	71,653 Added 230.86%	102,690 $21.8 Million
Q3 2021 Oct 13, 2021	SELL	$212.27 - $248.7 $15 Million - $17.6 Million	-70,627 Reduced 69.47%	31,037 $2.62 Million
Q2 2021 Jul 21, 2021	BUY	$233.58 - $259.14 $47,883 - $53,123	205 Added 0.2%	101,664 $24.8 Million
Q1 2021 Apr 15, 2021	SELL	$221.91 - $258.6 $745,617 - $868,896	-3,360 Reduced 3.21%	101,459 $25.2 Million
Q4 2020 Jan 14, 2021	BUY	$216.38 - $257.67 $10.6 Million - $12.6 Million	48,907 Added 87.47%	104,819 $24.1 Million
Q3 2020 Oct 08, 2020	BUY	$234.65 - $260.95 $71,098 - $79,067	303 Added 0.54%	55,912 $14.2 Million
Q2 2020 Aug 14, 2020	BUY	$197.81 - $242.74 $619,145 - $759,776	3,130 Added 5.96%	55,609 $13.1 Million
Q1 2020 Apr 28, 2020	BUY	$182.24 - $241.7 $190,076 - $252,093	1,043 Added 2.03%	52,479 $10.6 Million
Q4 2019 Feb 06, 2020	SELL	$189.21 - $243.2 $735,648 - $945,561	-3,888 Reduced 7.03%	51,436 $12.4 Million
Q3 2019 Oct 09, 2019	SELL	$174.11 - $208.62 $1.11 Million - $1.33 Million	-6,353 Reduced 10.3%	55,324 $10.7 Million
Q2 2019 Jul 09, 2019	SELL	$166.7 - $195.41 $296,726 - $347,829	-1,780 Reduced 2.81%	61,677 $11.4 Million
Q1 2019 May 02, 2019	SELL	$180.87 - $203.88 $299,158 - $337,217	-1,654 Reduced 2.54%	63,457 $12.1 Million
Q4 2018 Jan 31, 2019	SELL	$178.4 - $208.25 $858,996 - $1 Million	-4,815 Reduced 6.89%	65,111 $12.7 Million
Q3 2018 Nov 08, 2018	SELL	$185.29 - $208.89 $990,560 - $1.12 Million	-5,346 Reduced 7.1%	69,926 $14.5 Million
Q2 2018 Jul 31, 2018	SELL	$166.05 - $186.51 $8.02 Million - $9.01 Million	-48,315 Reduced 39.09%	75,272 $13.9 Million
Q1 2018 Apr 16, 2018	SELL	$169.43 - $198.0 $1.54 Million - $1.8 Million	-9,084 Reduced 6.85%	123,587 $21.1 Million
Q4 2017 Feb 05, 2018	BUY	$168.79 - $188.59 $899,819 - $1.01 Million	5,331 Added 4.19%	132,671 $23.1 Million
Q3 2016 Oct 25, 2017	BUY	N/A	127,340	127,340 $23.7 Million

Others Institutions Holding AMGN

# of Institutions

3,054

Shares Held

409M

Call Options Held

7.19M

Put Options Held

6.26M

View Full List

About AMGEN INC

Ticker AMGN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 534,931,008
Market Cap $173B
Description
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...

More about AMGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Crossmark Global Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Crossmark Global Holdings, Inc. with notifications on news.

Account

Crossmark Global Holdings, Inc. Amgen Inc Transaction History